Tej D Azad1, Aadel A Chaudhuri2, Penny Fang3, Yawei Qiao3, Mohammad S Esfahani1, Jacob J Chabon1, Emily G Hamilton1, Yi D Yang1, Alex Lovejoy1, Aaron M Newman4, David M Kurtz5, Michael Jin5, Joseph Schroers-Martin5, Henning Stehr1, Chih Long Liu6, Angela Bik-Yu Hui6, Viren Patel7, Dipen Maru7, Steven H Lin8, Ash A Alizadeh9, Maximilian Diehn10. 1. Department of Radiation Oncology, Stanford University, Stanford, California; Stanford Cancer Institute, Stanford University, Stanford, California. 2. Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Stanford Cancer Institute, Stanford University, Stanford, California; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California. 5. Stanford Cancer Institute, Stanford University, Stanford, California; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California. 6. Stanford Cancer Institute, Stanford University, Stanford, California. 7. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 8. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: shlin@mdanderson.org. 9. Stanford Cancer Institute, Stanford University, Stanford, California; Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, California. Electronic address: arasha@stanford.edu. 10. Department of Radiation Oncology, Stanford University, Stanford, California; Stanford Cancer Institute, Stanford University, Stanford, California; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, California. Electronic address: diehn@stanford.edu.
Abstract
BACKGROUND & AIMS: Biomarkers are needed to risk stratify after chemoradiotherapy for localized esophageal cancer. These could improve identification of patients at risk for cancer progression and selection of additional therapy. METHODS: We performed deep sequencing (CAncer Personalized Profiling by deep Sequencing, [CAPP-Seq]) analyses of plasma cell-free DNA collected from 45 patients before and after chemoradiotherapy for esophageal cancer, as well as DNA from leukocytes and fixed esophageal tumor biopsy samples collected during esophagogastroduodenoscopy. Patients were treated from May 2010 through October 2015; 23 patients subsequently underwent esophagectomy, and 22 did not undergo surgery. We also sequenced DNA from blood samples from 40 healthy control individuals. We analyzed 802 regions of 607 genes for single-nucleotide variants previously associated with esophageal adenocarcinoma or squamous cell carcinoma. Patients underwent imaging analyses 6-8 weeks after chemoradiotherapy and were followed for 5 years. Our primary aim was to determine whether detection of circulating tumor DNA (ctDNA) after chemoradiotherapy is associated with risk of tumor progression (growth of local, regional, or distant tumors, detected by imaging or biopsy). RESULTS: The median proportion of tumor-derived DNA in total cell-free DNA before treatment was 0.07%, indicating that ultrasensitive assays are needed for quantification and analysis of ctDNA from localized esophageal tumors. Detection of ctDNA after chemoradiotherapy was associated with tumor progression (hazard ratio, 18.7; P < .0001), formation of distant metastases (hazard ratio, 32.1; P < .0001), and shorter disease-specific survival times (hazard ratio, 23.1; P < .0001). A higher proportion of patients with tumor progression had new mutations detected in plasma samples collected after chemoradiotherapy than patients without progression (P = .03). Detection of ctDNA after chemoradiotherapy preceded radiographic evidence of tumor progression by an average of 2.8 months. Among patients who received chemoradiotherapy without surgery, combined ctDNA and metabolic imaging analysis predicted progression in 100% of patients with tumor progression, compared with 71% for only ctDNA detection and 57% for only metabolic imaging analysis (P < .001 for comparison of either technique to combined analysis). CONCLUSIONS: In an analysis of cell-free DNA in blood samples from patients who underwent chemoradiotherapy for esophageal cancer, detection of ctDNA was associated with tumor progression, metastasis, and disease-specific survival. Analysis of ctDNA might be used to identify patients at highest risk for tumor progression.
BACKGROUND & AIMS: Biomarkers are needed to risk stratify after chemoradiotherapy for localized esophageal cancer. These could improve identification of patients at risk for cancer progression and selection of additional therapy. METHODS: We performed deep sequencing (CAncer Personalized Profiling by deep Sequencing, [CAPP-Seq]) analyses of plasma cell-free DNA collected from 45 patients before and after chemoradiotherapy for esophageal cancer, as well as DNA from leukocytes and fixed esophageal tumor biopsy samples collected during esophagogastroduodenoscopy. Patients were treated from May 2010 through October 2015; 23 patients subsequently underwent esophagectomy, and 22 did not undergo surgery. We also sequenced DNA from blood samples from 40 healthy control individuals. We analyzed 802 regions of 607 genes for single-nucleotide variants previously associated with esophageal adenocarcinoma or squamous cell carcinoma. Patients underwent imaging analyses 6-8 weeks after chemoradiotherapy and were followed for 5 years. Our primary aim was to determine whether detection of circulating tumor DNA (ctDNA) after chemoradiotherapy is associated with risk of tumor progression (growth of local, regional, or distant tumors, detected by imaging or biopsy). RESULTS: The median proportion of tumor-derived DNA in total cell-free DNA before treatment was 0.07%, indicating that ultrasensitive assays are needed for quantification and analysis of ctDNA from localized esophageal tumors. Detection of ctDNA after chemoradiotherapy was associated with tumor progression (hazard ratio, 18.7; P < .0001), formation of distant metastases (hazard ratio, 32.1; P < .0001), and shorter disease-specific survival times (hazard ratio, 23.1; P < .0001). A higher proportion of patients with tumor progression had new mutations detected in plasma samples collected after chemoradiotherapy than patients without progression (P = .03). Detection of ctDNA after chemoradiotherapy preceded radiographic evidence of tumor progression by an average of 2.8 months. Among patients who received chemoradiotherapy without surgery, combined ctDNA and metabolic imaging analysis predicted progression in 100% of patients with tumor progression, compared with 71% for only ctDNA detection and 57% for only metabolic imaging analysis (P < .001 for comparison of either technique to combined analysis). CONCLUSIONS: In an analysis of cell-free DNA in blood samples from patients who underwent chemoradiotherapy for esophageal cancer, detection of ctDNA was associated with tumor progression, metastasis, and disease-specific survival. Analysis of ctDNA might be used to identify patients at highest risk for tumor progression.
Authors: Marinke Westerterp; Henderik L van Westreenen; Johannes B Reitsma; Otto S Hoekstra; Jaap Stoker; Paul Fockens; Pieter L Jager; Berthe L F Van Eck-Smit; John T M Plukker; J Jan B van Lanschot; Gerrit W Sloof Journal: Radiology Date: 2005-09 Impact factor: 11.105
Authors: Nishant Agrawal; Yuchen Jiao; Chetan Bettegowda; Susan M Hutfless; Yuxuan Wang; Stefan David; Yulan Cheng; William S Twaddell; Nyan L Latt; Eun J Shin; Li-Dong Wang; Liang Wang; Wancai Yang; Victor E Velculescu; Bert Vogelstein; Nickolas Papadopoulos; Kenneth W Kinzler; Stephen J Meltzer Journal: Cancer Discov Date: 2012-08-09 Impact factor: 39.397
Authors: Johannes B Roedl; Rivka R Colen; Nagaraj S Holalkere; Alan J Fischman; Noah C Choi; Michael A Blake Journal: Radiother Oncol Date: 2008-08-11 Impact factor: 6.280
Authors: Bo Jan Noordman; Manon C W Spaander; Roelf Valkema; Bas P L Wijnhoven; Mark I van Berge Henegouwen; Joël Shapiro; Katharina Biermann; Ate van der Gaast; Richard van Hillegersberg; Maarten C C M Hulshof; Kausilia K Krishnadath; Sjoerd M Lagarde; Grard A P Nieuwenhuijzen; Liekele E Oostenbrug; Peter D Siersema; Erik J Schoon; Meindert N Sosef; Ewout W Steyerberg; J Jan B van Lanschot Journal: Lancet Oncol Date: 2018-06-01 Impact factor: 41.316
Authors: Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs Journal: Sci Transl Med Date: 2016-07-06 Impact factor: 17.956
Authors: Christopher Abbosh; Nicolai J Birkbak; Gareth A Wilson; Mariam Jamal-Hanjani; Tudor Constantin; Raheleh Salari; John Le Quesne; David A Moore; Selvaraju Veeriah; Rachel Rosenthal; Teresa Marafioti; Eser Kirkizlar; Thomas B K Watkins; Nicholas McGranahan; Sophia Ward; Luke Martinson; Joan Riley; Francesco Fraioli; Maise Al Bakir; Eva Grönroos; Francisco Zambrana; Raymondo Endozo; Wenya Linda Bi; Fiona M Fennessy; Nicole Sponer; Diana Johnson; Joanne Laycock; Seema Shafi; Justyna Czyzewska-Khan; Andrew Rowan; Tim Chambers; Nik Matthews; Samra Turajlic; Crispin Hiley; Siow Ming Lee; Martin D Forster; Tanya Ahmad; Mary Falzon; Elaine Borg; David Lawrence; Martin Hayward; Shyam Kolvekar; Nikolaos Panagiotopoulos; Sam M Janes; Ricky Thakrar; Asia Ahmed; Fiona Blackhall; Yvonne Summers; Dina Hafez; Ashwini Naik; Apratim Ganguly; Stephanie Kareht; Rajesh Shah; Leena Joseph; Anne Marie Quinn; Phil A Crosbie; Babu Naidu; Gary Middleton; Gerald Langman; Simon Trotter; Marianne Nicolson; Hardy Remmen; Keith Kerr; Mahendran Chetty; Lesley Gomersall; Dean A Fennell; Apostolos Nakas; Sridhar Rathinam; Girija Anand; Sajid Khan; Peter Russell; Veni Ezhil; Babikir Ismail; Melanie Irvin-Sellers; Vineet Prakash; Jason F Lester; Malgorzata Kornaszewska; Richard Attanoos; Haydn Adams; Helen Davies; Dahmane Oukrif; Ayse U Akarca; John A Hartley; Helen L Lowe; Sara Lock; Natasha Iles; Harriet Bell; Yenting Ngai; Greg Elgar; Zoltan Szallasi; Roland F Schwarz; Javier Herrero; Aengus Stewart; Sergio A Quezada; Karl S Peggs; Peter Van Loo; Caroline Dive; C Jimmy Lin; Matthew Rabinowitz; Hugo J W L Aerts; Allan Hackshaw; Jacqui A Shaw; Bernhard G Zimmermann; Charles Swanton Journal: Nature Date: 2017-04-26 Impact factor: 49.962
Authors: Austin M Dulak; Petar Stojanov; Shouyong Peng; Michael S Lawrence; Cameron Fox; Chip Stewart; Santhoshi Bandla; Yu Imamura; Steven E Schumacher; Erica Shefler; Aaron McKenna; Scott L Carter; Kristian Cibulskis; Andrey Sivachenko; Gordon Saksena; Douglas Voet; Alex H Ramos; Daniel Auclair; Kristin Thompson; Carrie Sougnez; Robert C Onofrio; Candace Guiducci; Rameen Beroukhim; Zhongren Zhou; Lin Lin; Jules Lin; Rishindra Reddy; Andrew Chang; Rodney Landrenau; Arjun Pennathur; Shuji Ogino; James D Luketich; Todd R Golub; Stacey B Gabriel; Eric S Lander; David G Beer; Tony E Godfrey; Gad Getz; Adam J Bass Journal: Nat Genet Date: 2013-03-24 Impact factor: 38.330
Authors: John M Findlay; Francesc Castro-Giner; Seiko Makino; Emily Rayner; Christiana Kartsonaki; William Cross; Michal Kovac; Danny Ulahannan; Claire Palles; Richard S Gillies; Thomas P MacGregor; David Church; Nicholas D Maynard; Francesca Buffa; Jean-Baptiste Cazier; Trevor A Graham; Lai-Mun Wang; Ricky A Sharma; Mark Middleton; Ian Tomlinson Journal: Nat Commun Date: 2016-04-05 Impact factor: 14.919
Authors: Aadel A Chaudhuri; Bruna Pellini; Nadja Pejovic; Pradeep S Chauhan; Peter K Harris; Jeffrey J Szymanski; Zachary L Smith; Vivek K Arora Journal: JCO Precis Oncol Date: 2020-07-15
Authors: Jeanne Tie; Joshua D Cohen; Serigne N Lo; Yuxuan Wang; Lu Li; Michael Christie; Margaret Lee; Rachel Wong; Suzanne Kosmider; Iain Skinner; Hui Li Wong; Belinda Lee; Matthew E Burge; Desmond Yip; Christos S Karapetis; Timothy J Price; Niall C Tebbutt; Andrew M Haydon; Janine Ptak; Mary J Schaeffer; Natalie Silliman; Lisa Dobbyn; Maria Popoli; Cristian Tomasetti; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs Journal: Int J Cancer Date: 2020-10-06 Impact factor: 7.396
Authors: Bruna Pellini; Nadja Pejovic; Wenjia Feng; Noah Earland; Peter K Harris; Abul Usmani; Jeffrey J Szymanski; Faridi Qaium; Jacqueline Mudd; Marvin Petty; Yuqiu Jiang; Ashla Singh; Christopher A Maher; Lauren E Henke; Haeseong Park; Matthew A Ciorba; Hyun Kim; Matthew G Mutch; Katrina S Pedersen; Benjamin R Tan; William G Hawkins; Ryan C Fields; Aadel A Chaudhuri Journal: JCO Precis Oncol Date: 2021-02-12